Lynn E. Fleckenstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lynn E. Fleckenstein has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
- Erin J. Aiello Bowles
Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA
3 shared publications - Larry Kessler
Department of Health Systems and Population Health School of Public Health University of Washington Seattle Washington USA
3 shared publications - Anamika Agrawal
Allen Institute, Center for Data-Driven Discovery, Seattle, WA
2 shared publications - Augustin Ruiz
Allen Institute for Brain Science
2 shared publications - Boaz P. Levi
Allen Institute, Brain Health, Seattle, 98109, WA, USA
2 shared publications - Brian E. Kalmbach
Allen Institute for Brain Science
2 shared publications
Latest Publications
- Open Access
Multiregional single-cell profiling reveals shared and specialized cellular vulnerability in Alzheimer’s disease
Alzheimer’s disease (AD) is defined and staged by the stereotyped, progressive accumulation of amyloid-beta (Aβ) plaques and hyperphosphorylated tau (pTau) tangles across brain regions. These regions differ substantially in their architecture and function but share largely conserved cellular composition, with some regional specialization. As pathology accumulates, specific neurons are lost and non-neuronal cells shift toward disease-associated states, but whether the cell types affected in any one region are the same across the others has remained unclear. Here we extended the Seattle Alzheimer’s Disease Brain Cell Atlas (SEA-AD) to ten neo- and allocortical regions spanning the cortical arc of canonical AD staging, profiling approximately seven million nuclei from 84 donors with single-nucleus RNA-seq, ATAC-seq, and Multiome alongside quantitative neuropathology and whole-genome sequencing. Nuclei were mapped to an expanded BRAIN Initiative reference taxonomy of 207 cell types, and a hierarchical pseudo-progression framework derived continuous, donor-level measures of AD pathological burden within each region and across the brain by jointly modeling Aβ and pTau. Cellular changes were both highly selective and strikingly consistent: only ∼30% of cell types shifted in relative abundance, but those that did changed in a coherent direction across regions. Specific subsets of Sst, Lamp5, Vip, Sncg, and Pvalb inhibitory interneurons and myelinating oligodendrocytes were lost earliest in preclinical donors with minimal pathology, alongside initial emergence of AD-associated microglia; loss of L2/3 and selected deep-layer excitatory types, sharper microglial increases, and reactive astrocyte emergence followed in later-stage donors. Regionally specialized populations were also vulnerable, including expected allocortical types and, unexpectedly, primary visual cortex (V1C)-specialized layer 4 (L4 IT) excitatory neurons and intermixed Sst and Pvalb interneurons. Key changes replicated across three independent cohorts encompassing over 700 additional donors. We examined two complementary vulnerable populations in mechanistic detail: regionally specialized V1C L4 IT neurons lost late despite being widely considered resilient, and pan-cortical Sst interneurons lost earliest in disease. Applying a multi-agentic AI workflow that constructed literature-grounded hypotheses from differential expression to L4 IT neurons nominated hyperexcitability, mediated in part by high NMDA receptor expression, as a convergent vulnerability phenotype. Vulnerable Sst interneurons converged on hyperexcitability through partly distinct pathways, and were enriched for expression of AD GWAS-prioritized genes, linking their vulnerability to the genetic architecture of AD. These data, available at SEA-AD.org, provide a multiregional framework for the community to explore the molecular and cellular changes of AD progression.
Open AccessMultiregional single-cell profiling reveals shared and specialized cellular vulnerability in Alzheimer’s disease
Alzheimer’s disease (AD) is defined and staged by the stereotyped, progressive accumulation of amyloid-beta (Aβ) plaques and hyperphosphorylated tau (pTau) tangles across brain regions. These regions differ substantially in their architecture and function but share largely conserved cellular composition, with some regional specialization. As pathology accumulates, specific neurons are lost and non-neuronal cells shift toward disease-associated states, but whether the cell types affected in any one region are the same across the others has remained unclear. Here we extended the Seattle Alzheimer’s Disease Brain Cell Atlas (SEA-AD) to ten neo- and allocortical regions spanning the cortical arc of canonical AD staging, profiling approximately seven million nuclei from 84 donors with single-nucleus RNA-seq, ATAC-seq, and Multiome alongside quantitative neuropathology and whole-genome sequencing. Nuclei were mapped to an expanded BRAIN Initiative reference taxonomy of 207 cell types, and a hierarchical pseudo-progression framework derived continuous, donor-level measures of AD pathological burden within each region and across the brain by jointly modeling Aβ and pTau. Cellular changes were both highly selective and strikingly consistent: only ∼30% of cell types shifted in relative abundance, but those that did changed in a coherent direction across regions. Specific subsets of Sst, Lamp5, Vip, Sncg, and Pvalb inhibitory interneurons and myelinating oligodendrocytes were lost earliest in preclinical donors with minimal pathology, alongside initial emergence of AD-associated microglia; loss of L2/3 and selected deep-layer excitatory types, sharper microglial increases, and reactive astrocyte emergence followed in later-stage donors. Regionally specialized populations were also vulnerable, including expected allocortical types and, unexpectedly, primary visual cortex (V1C)-specialized layer 4 (L4 IT) excitatory neurons and intermixed Sst and Pvalb interneurons. Key changes replicated across three independent cohorts encompassing over 700 additional donors. We examined two complementary vulnerable populations in mechanistic detail: regionally specialized V1C L4 IT neurons lost late despite being widely considered resilient, and pan-cortical Sst interneurons lost earliest in disease. Applying a multi-agentic AI workflow that constructed literature-grounded hypotheses from differential expression to L4 IT neurons nominated hyperexcitability, mediated in part by high NMDA receptor expression, as a convergent vulnerability phenotype. Vulnerable Sst interneurons converged on hyperexcitability through partly distinct pathways, and were enriched for expression of AD GWAS-prioritized genes, linking their vulnerability to the genetic architecture of AD. These data, available at SEA-AD.org, provide a multiregional framework for the community to explore the molecular and cellular changes of AD progression.
- Open Access
- 1 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0352356
Reliability of cancer screening questions from the National Health Interview Survey
Background: The National Health Interview Survey (NHIS), a nationwide in-person and telephone survey of the civilian non-institutionalized population, is used to measure progress towards Healthy People objectives on cancer screening. Survey reports have been compared to medical record data to assess validity of these questions; however, few studies have assessed reliability, or response consistency over time. We assessed the test-retest reliability of questions on cervical, colorectal, breast and lung cancer screening from the 2021 and 2022 NHIS. Methods: We surveyed 1,770 adults ages 18 + years with and without prior screening for breast, cervical, colorectal, and lung cancer from four U.S. health systems (three in Washington state and one in Michigan) to examine validity of the NHIS questions. Among people who completed the validity survey, we randomized individuals to receive an additional survey one month later (N = 944) and three months later (N = 822). We calculated Cohen’s Kappa, Gwet’s AC1, and simple concordance to assess reliability. Results: Among our study sample, 535 (56.7% of those assigned) to one month follow-up and 537 (65.0%) assigned to three month follow-up completed the reliability survey. Among these, 36 (6.6%) and 94 (17.6%) of those assigned to one and three month follow-up respectively were excluded from reliability analyses because they had additional screening tests after completing the validity survey. Cohen’s Kappa showed strong-to-moderate reliability for being up to date with mammography screening: 0.83 at one month and 0.78 at three months; reliability for other screening tests was considerably lower: 0.61 and 0.60 for cervical, 0.57 and 0.62 for colorectal, and 0.72 and 0.58 for lung and one and three months, respectively. Conclusions: We found strong-to-moderate reliability of responses recalling breast cancer screening at one and three months following an initial survey. Reliability may not be a major threat to self-reported cancer screening behavior.
- 1 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0352356
Open AccessReliability of cancer screening questions from the National Health Interview Survey
Background: The National Health Interview Survey (NHIS), a nationwide in-person and telephone survey of the civilian non-institutionalized population, is used to measure progress towards Healthy People objectives on cancer screening. Survey reports have been compared to medical record data to assess validity of these questions; however, few studies have assessed reliability, or response consistency over time. We assessed the test-retest reliability of questions on cervical, colorectal, breast and lung cancer screening from the 2021 and 2022 NHIS. Methods: We surveyed 1,770 adults ages 18 + years with and without prior screening for breast, cervical, colorectal, and lung cancer from four U.S. health systems (three in Washington state and one in Michigan) to examine validity of the NHIS questions. Among people who completed the validity survey, we randomized individuals to receive an additional survey one month later (N = 944) and three months later (N = 822). We calculated Cohen’s Kappa, Gwet’s AC1, and simple concordance to assess reliability. Results: Among our study sample, 535 (56.7% of those assigned) to one month follow-up and 537 (65.0%) assigned to three month follow-up completed the reliability survey. Among these, 36 (6.6%) and 94 (17.6%) of those assigned to one and three month follow-up respectively were excluded from reliability analyses because they had additional screening tests after completing the validity survey. Cohen’s Kappa showed strong-to-moderate reliability for being up to date with mammography screening: 0.83 at one month and 0.78 at three months; reliability for other screening tests was considerably lower: 0.61 and 0.60 for cervical, 0.57 and 0.62 for colorectal, and 0.72 and 0.58 for lung and one and three months, respectively. Conclusions: We found strong-to-moderate reliability of responses recalling breast cancer screening at one and three months following an initial survey. Reliability may not be a major threat to self-reported cancer screening behavior.
- Open Access
- 30 April 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (3)
Accuracy of self-reported exam indications for breast cancer screening
We validated updated National Health Interview Survey questions on mammography indications compared with electronic health records (EHRs). We asked 244 Kaiser Permanente Washington members ages 40-74 years and eligible for breast cancer screening to self-report their most recent mammogram reason by using a series of new hierarchical yes/no questions. We first asked if they had the mammogram because of a health problem, then as a follow-up test, and last for screening. We compared self-reported reasons with 2 EHR datasets: procedure/diagnostic codes and radiologist-defined indications. Self-reported exams for a health problem had 89.2% agreement with codes and 92.2% agreement with radiologist-defined indications. Self-reported exams for follow-up had 87.5% agreement with codes and 89.3% agreement with radiologist-defined indications. Self-reported exams for screening had 91.4% agreement with codes and 95.7% agreement with radiologist-defined indications. Self-reported mammogram indications have good agreement with procedure/diagnostic codes and radiologist-reported indications, when asked using this novel hierarchical approach.
- 30 April 2025
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (3)
Open AccessAccuracy of self-reported exam indications for breast cancer screening
We validated updated National Health Interview Survey questions on mammography indications compared with electronic health records (EHRs). We asked 244 Kaiser Permanente Washington members ages 40-74 years and eligible for breast cancer screening to self-report their most recent mammogram reason by using a series of new hierarchical yes/no questions. We first asked if they had the mammogram because of a health problem, then as a follow-up test, and last for screening. We compared self-reported reasons with 2 EHR datasets: procedure/diagnostic codes and radiologist-defined indications. Self-reported exams for a health problem had 89.2% agreement with codes and 92.2% agreement with radiologist-defined indications. Self-reported exams for follow-up had 87.5% agreement with codes and 89.3% agreement with radiologist-defined indications. Self-reported exams for screening had 91.4% agreement with codes and 95.7% agreement with radiologist-defined indications. Self-reported mammogram indications have good agreement with procedure/diagnostic codes and radiologist-reported indications, when asked using this novel hierarchical approach.
- Top Cited PapersOpen Access
- 14 October 2024
- Published by Springer Nature in Nature Neuroscience
- Vol. 27 (12) , 2366-2383
Integrated multimodal cell atlas of Alzheimer’s disease
Alzheimer’s disease (AD) is the leading cause of dementia in older adults. Although AD progression is characterized by stereotyped accumulation of proteinopathies, the affected cellular populations remain understudied. Here we use multiomics, spatial genomics and reference atlases from the BRAIN Initiative to study middle temporal gyrus cell types in 84 donors with varying AD pathologies. This cohort includes 33 male donors and 51 female donors, with an average age at time of death of 88 years. We used quantitative neuropathology to place donors along a disease pseudoprogression score. Pseudoprogression analysis revealed two disease phases: an early phase with a slow increase in pathology, presence of inflammatory microglia, reactive astrocytes, loss of somatostatin + inhibitory neurons, and a remyelination response by oligodendrocyte precursor cells; and a later phase with exponential increase in pathology, loss of excitatory neurons and Pvalb + and Vip + inhibitory neuron subtypes. These findings were replicated in other major AD studies.
- 14 October 2024
- Published by Springer Nature in Nature Neuroscience
- Vol. 27 (12) , 2366-2383
Top Cited PapersOpen AccessIntegrated multimodal cell atlas of Alzheimer’s disease
Alzheimer’s disease (AD) is the leading cause of dementia in older adults. Although AD progression is characterized by stereotyped accumulation of proteinopathies, the affected cellular populations remain understudied. Here we use multiomics, spatial genomics and reference atlases from the BRAIN Initiative to study middle temporal gyrus cell types in 84 donors with varying AD pathologies. This cohort includes 33 male donors and 51 female donors, with an average age at time of death of 88 years. We used quantitative neuropathology to place donors along a disease pseudoprogression score. Pseudoprogression analysis revealed two disease phases: an early phase with a slow increase in pathology, presence of inflammatory microglia, reactive astrocytes, loss of somatostatin + inhibitory neurons, and a remyelination response by oligodendrocyte precursor cells; and a later phase with exponential increase in pathology, loss of excitatory neurons and Pvalb + and Vip + inhibitory neuron subtypes. These findings were replicated in other major AD studies.
- Open Access
- 4 March 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (3) , e0297773
Protocol to measure validity and reliability of colorectal, breast, cervical and lung cancer screening questions from the 2021 National Health Interview Survey: Methodology and design
Previous studies demonstrate that self-reports of mammography screening for breast cancer and colonoscopy screening for colorectal cancer demonstrate concordance, based on adherence to screening guidelines, with electronic medical records (EMRs) in over 90% of those interviewed, as well as high sensitivity and specificity, and can be used for monitoring our Healthy People goals. However, for screening tests for cervical and lung cancers, and for various sub-populations, concordance between self-report and EMRs has been noticeably lower with poor sensitivity or specificity. This study aims to test the validity and reliability of lung, colorectal, cervical, and breast cancer screening questions from the 2021 and 2022 National Health Interview Survey (NHIS). We present the protocol for a study designed to measure the validity and reliability of the NHIS cancer screening questions compared to EMRs from four US-based healthcare systems. We planned a randomized trial of a phone- vs web-based survey with NHIS questions that were previously revised based on extensive cognitive interviewing. Our planned sample size will be 1576 validity interviews, and 1260 interviews randomly assigned at 1 or 3 months after the initial interview. We are enrolling people eligible for cancer screening based on age, sex, and smoking history per US Preventive Services Task Force recommendations. We will evaluate question validity using concordance, sensitivity, specificity, positive predictive value, negative predictive value, and report-to-records ratio. We further are randomizing participants to complete a second survey 1 vs 3 months later to assess question reliability. We suggest that typical measures of concordance may need to be reconsidered in evaluating cancer screening questions.
- 4 March 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (3) , e0297773
Open AccessProtocol to measure validity and reliability of colorectal, breast, cervical and lung cancer screening questions from the 2021 National Health Interview Survey: Methodology and design
Previous studies demonstrate that self-reports of mammography screening for breast cancer and colonoscopy screening for colorectal cancer demonstrate concordance, based on adherence to screening guidelines, with electronic medical records (EMRs) in over 90% of those interviewed, as well as high sensitivity and specificity, and can be used for monitoring our Healthy People goals. However, for screening tests for cervical and lung cancers, and for various sub-populations, concordance between self-report and EMRs has been noticeably lower with poor sensitivity or specificity. This study aims to test the validity and reliability of lung, colorectal, cervical, and breast cancer screening questions from the 2021 and 2022 National Health Interview Survey (NHIS). We present the protocol for a study designed to measure the validity and reliability of the NHIS cancer screening questions compared to EMRs from four US-based healthcare systems. We planned a randomized trial of a phone- vs web-based survey with NHIS questions that were previously revised based on extensive cognitive interviewing. Our planned sample size will be 1576 validity interviews, and 1260 interviews randomly assigned at 1 or 3 months after the initial interview. We are enrolling people eligible for cancer screening based on age, sex, and smoking history per US Preventive Services Task Force recommendations. We will evaluate question validity using concordance, sensitivity, specificity, positive predictive value, negative predictive value, and report-to-records ratio. We further are randomizing participants to complete a second survey 1 vs 3 months later to assess question reliability. We suggest that typical measures of concordance may need to be reconsidered in evaluating cancer screening questions.